Overview

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-387
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical